Evaluation of Miricorilant on Liver Fat in Patients With MASLD

NCT ID: NCT06947304

Last Updated: 2025-10-16

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 8 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-08-22
• Study Completion Date: 2026-03-31

Brief Summary

A Phase 1, Open-Label Study Evaluating the Effect of Miricorilant on Hepatic Lipids in Patients with Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Detailed Description

Approximately 8 patients who are eligible for participation in the study will be assigned to a single dose cohort receiving 100 mg of miricorilant daily. The total duration of participation for each patient is expected to be up to 14 weeks, comprising a 6-week screening period, a 4-week treatment phase, and a 4-week follow-up period.

Conditions

Nonalcoholic Steatohepatitis (NASH); Metabolic Dysfunction-Associated Steatohepatitis (MASH); Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD); Non-alcoholic Fatty Liver Disease (NAFLD)

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Miricorilant- 100 mg

Patients who meet the entry criteria for study CORT118335-858 will be enrolled to receive 100 mg of miricorilant every day for 4 weeks.

Group Type: EXPERIMENTAL

Miricorilant

Intervention Type: DRUG

100 mg administered orally, once daily

Interventions

Miricorilant

100 mg administered orally, once daily

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• AST > 17 U/L for women and AST > 20 U/L for men. The AST inclusion criterion does not apply to participants with an eligible historical liver biopsy performed within 12 months of screening showing one of the following:

1. NAFLD Activity Score (NAS) ≥ 4 (with at least 1 point in each subcomponent of steatosis, inflammation, and ballooning) and NASH Clinical Research Network (CRN) fibrosis score of F0 OR

2. NAS ≥ 3 (with at least 1 point in each subcomponent of steatosis, inflammation, and ballooning) and NASH CRN fibrosis score of F1 OR

3. NAS ≥ 2 (with at least 1 point in subcomponent of ballooning or inflammation) and a NASH CRN fibrosis score of F2-3

• MRI-PDFF with ≥ 8% steatosis; this assessment must be performed within 4 weeks of the Baseline Visit.
• Presence of at least 1 of the following metabolic syndrome characteristics that increase the risk of MASH:

a. Diagnosis of type 2 diabetes managed with diet alone or diet and metformin (metformin dose must be stable for at least 1 month prior to screening) OR b. Presence of 3 or more components of metabolic syndrome: i. Fasting blood glucose ≥ 100 mg/dL (5.6 mmol/L) or treatment for elevated blood glucose with metformin ii. Systolic blood pressure ≥ 130 mm Hg, diastolic blood pressure ≥ 85 mm Hg, or treatment for hypertension iii. Serum TG ≥ 150 mg/dL (1.7 mmol/L) iv. Serum high-density lipoprotein cholesterol (HDL) < 40 mg/dL (1 mmol/L) in men and < 50 mg/dL (1.3 mmol/L) in women or drug treatment for low HDL v. Having overweight or obesity (body mass index [BMI] ≥ 25 kg/m2 [BMI

• 23 kg/m2 in Asians]), or increased waist circumference ≥ 102 cm (40 in) in men and ≥ 88 cm (35 in) in women (men ≥ 90 cm [35.4 in]; women ≥ 80 cm [31.5 in] in Asians).

Exclusion Criteria

• Participation in another clinical trial for MASH or weight loss (e.g., GLP-1 receptor agonists) within the last 3 months.
• Participation in any other clinical trial within the last 3 months or 5 half-lives of the treatment, whichever is longer.
• Women who are pregnant, planning to become pregnant, or lactating.
• BMI < 18 kg/m² or > 45 kg/m².
• Significant alcohol consumption exceeding 20 g/day for women or 30 g/day for men within 1 year prior to screening.
• Positive urine drug screen for amphetamines, cocaine, opiates, or cannabinoids.
• Known or suspected cirrhosis or signs of hepatic decompensation.
• Other chronic liver diseases such as hepatitis B or C, autoimmune hepatitis, primary biliary cholangitis, or Wilson's disease.
• History of myocardial infarction, unstable angina, or stroke within 3 months prior to screening.
• Uncontrolled hypertension (systolic > 160 mm Hg or diastolic > 100 mm Hg).
• Current use of medications prohibited due to potential drug-drug interactions with study treatment.
• Contraindications to magnetic resonance imaging (MRI).

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Missouri-Columbia

OTHER

Sponsor Role: collaborator

Corcept Therapeutics

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Kavita Juneja, MD

Role: STUDY_DIRECTOR

Corcept Therapeutics

Locations

University of Missouri

Columbia, Missouri, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Elizabeth Parks, PhD

Role: CONTACT

parksej@missouri.edu

(573) 882-5864

Facility Contacts

Elizabeth Parks, PhD

Role: primary

parksej@missouri.edu

(573) 882-5864

Jessica George, BS

Role: backup

jgmft7@mail.missouri.edu

(573) 884-2014

Other Identifiers

CORT118335-858

Identifier Type: -

Identifier Source: org_study_id